TABLE 5.
Sensitivity Analyses of Survival in Patients Receiving Pirfenidone and BSC Using Alternative Distributions
| Sensitivity Analysis | Mean Survival (95% CI), Years | ||
|---|---|---|---|
| Pirfenidone | BSC | Difference | |
| Parametric Distributions for Pirfenidone and BSC | |||
| Log-logistic | 11.24 (9.87-12.82) | 7.72 (6.51-9.01) | 3.52 (1.86-5.57) |
| Gompertz | 8.35 (7.44-10.31) | 6.39 (5.54-7.96) | 1.95 (1.27-3.24) |
| Inverse-gamma | 9.53 (7.98-12.37) | 6.40 (5.44-7.58) | 3.12 (1.56-6.05) |
| Exponential | 11.95 (11.82-12.06) | 6.61 (6.54-6.68) | 5.34 (5.20-5.49) |
| Log-normal | 12.74 (10.93-14.40) | 8.76 (7.29-10.24) | 3.98 (1.79-6.14) |
| Alternative Methods for Calculating BSC Survival | |||
| Applying NMA HRa to the pirfenidone survival distribution | 8.72 (7.75-10.26) | 5.42 (3.16-8.15) | 3.29 (0.79-5.77) |
| Parametric approach; Weibull distributions calculated using only Inova registry data | 8.72 (7.66-10.19) | 5.88 (5.05-6.96) | 2.83 (1.54-4.46) |
| Alternative Methods for Calculating Pirfenidone Survival | |||
| Conservative piecewise approach; pirfenidone has the same effect on survival as BSC after 5 years | 7.79 (6.95-8.74) | 6.24 (5.39-7.33) | 1.54 (1.06-1.95) |
aSee “Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatment” on page S5 of this supplement.
BSC = best supportive care; CI = confidence interval; HR = hazard ratio; NMA = network meta-analysis.